Alopros 5

Each capsule contains Finasteride 5 mg.

Finasteride is a competitive and specific inhibitor of Type II 5-α-reductase. Finasteride has no affinity for the androgenic, antiandrogenic, estrogenic, antiestrogenic, or progestational effect. Inhibition of this enzyme blocks the peripheral conversion of testosterone to the androgen dihydrotestosterone (DHT), resulting in significant decreases in serum and tissue DHT concentrations. Circulating levels of testosterone were increased by approximately 10-15% compared with placebo, yet remained within the physiologic range. Finasteride produces a rapid reduction in serum DHT concentration, reaching significant suppression within 24 hours of dosing. In Benign Prostatic Hyperplasia (BPH), enlargement of the prostate gland is dependent upon the conversion of testosterone to DHT within the prostate. Finasteride is effective in reducing circulating and intraprostatic DHT.

For the treatment and control of Benign Prostatic Hyperplasia (BPH) in patients with an enlarged prostate to cause regression of the enlarged prostate, improve urinary flow, and improve the symptoms associated with BPH.

The recommended dosage, is one capsule per day.
The patient may take this product either with a meal or between meals.
A minimum of 6 months of treatment may be necessary to determine whether an individual will respond to Finasteride. No dosage adjustment is necessary in patients with renal function abnormalities and in elderly.

Patient with hypersensitivity to Finasteride and any component of this product.
Women, nursing women, pregnant women or may potentially be pregnant because of the ability of the type II 5-α-reductase inhibitors to inhibit the conversion of testosterone to DHT, Finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant women who receives Finasteride.
Children.

No clinical benefit has been demonstrated in patients with prostate cancer treated with Finasteride. Prior to initiating therapy with Finasteride appropriate evaluation should be performed to identify other conditions such as prostate cancer.
No dosage adjustment is necessary in the elderly (70 and over), although the elimination rate of Finasteride is decreased in the elderly.
Is not indicated for use in pregnant and nursing women, and children.
Should be carefully monitored for obstructive uropathy.
Caution should be used in the administration of Finasteride in those patients with liver function abnormalities.
After 6 months of treatment should be necessary to evaluated.

Adverse reactions may include decreased amount of semen per ejaculation, decreased libido, and impotence. Hypersensitivity reaction including skin rash, swelling of the lips, breast tenderness, and enlargement.

There is no clinical data about the interaction between Finasteride with any other drug.

Store below 30°C.

Drugs for Bladder & Prostate Disorders

G04CB01 - finasteride ; Belongs to the class of testosterone-5-alpha reductase inhibitors. Used in the treatment of benign prostatic hypertrophy.

K